, Tracking Stock Market Picks
Enter Symbol:
Navidea Biopharmaceuticals Inc. (NAVB) [hlAlert]

Mkt Outperform
down 39.79 %

Neoprobe Corp. (NAVB) rated Mkt Outperform with price target $5 by Burrill Institutional Research

Posted on: Thursday,  Jan 24, 2013  9:25 AM ET by Burrill Institutional Research

Burrill Institutional Research rated Mkt Outperform Navidea Biopharmaceuticals Inc. (AMEX: NAVB) on 01/24/2013, when the stock price was $2.99.
Since then, Navidea Biopharmaceuticals Inc. has lost 39.80% as of 08/27/2015's recent price of $1.80.
If you would have followed this Burrill Institutional Research's recommendation on NAVB, you would have lost 39.79% of your investment in 945 days.

Neoprobe Corporation (Neoprobe) is a biomedical company that develops and commercializes products that enhance patient care and improve patient outcome by meeting the intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. The Company markets two lines of medical devices, which includes its neoprobe GDS gamma detection systems and the Quantix line of blood flow measurement devices of its subsidiary, Cardiosonix Ltd. In addition to its medical device products, it has two radiopharmaceutical products, Lymphoseek and RIGScan CR, in advanced phases of clinical development.

Burrill Institutional Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/24/2013 9:25 AM Buy
2.99 5.00
as of 12/13/2013
1 Week up  13.40 %
1 Month up  36.24 %
3 Months down  -29.75 %
1 YTD down  -32.10 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy